Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human Tie-1 Antibody, R&D Systems™

Mouse Monoclonal Antibody has been used in 2 publications
Supplier: R&D Systems MAB619
This item is not returnable.
View return policy
Description
Tie-1 Monoclonal specifically detects Tie-1 in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunocytochemistry.Specifications
Tie-1 | |
Monoclonal | |
Unconjugated | |
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 μm filtered solution in PBS. with No Preservative | |
EC 2.7.10, EC 2.7.10.1, JTK14soluble TIE1 variant 3, receptor tyrosine kinase, soluble TIE1 variant 1, soluble TIE1 variant 2, soluble TIE1 variant 5, Tie1, TIEsoluble TIE1 variant 4, tyrosine kinase with immunoglobulin and epidermal growth factor homologydomains 1, tyrosine kinase with immunoglobulin-like and EGF-like domains 1, tyrosine-protein kinase receptor Tie-1 | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
7075 | |
Reconstitute at 0.5 mg/mL in sterile PBS. | |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution. | |
IgG1 |
Western Blot, Immunohistochemistry, Immunocytochemistry | |
88016 | |
Western Blot 1 ug/mL, Immunohistochemistry 8-25 ug/mL, Immunocytochemistry 8-25 ug/mL | |
P35590 | |
TIE1 | |
Mouse myeloma cell line NS0-derived recombinant human Tie-1 Ala22-Gln760 (predicted) Accession # P35590 | |
500 μg | |
Primary | |
Detects human Tie-1 in direct ELISAs and Western blots. | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction